Galderma (Switzerland)

Recent papers from Galderma (Switzerland)

1. Lifestyle-Driven Phenotypes in Sensitive Skin: A Cross-Sectional, Multicenter Study Across Urbanization TiersDermatology and Therapy · 2026
2. Development of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 TrialDermatology and Therapy · 2026
3. Temporally Optimized Antioxidant Serums for Daytime Defense and Nighttime Repair: A Multicenter Clinical InvestigationDermatology and Therapy · 2026
4. Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate‐to‐Severe Atopic DermatitisAllergy · 2026
5. Randomized Controlled Study of Nemolizumab in Patients With Chronic Kidney Disease and Associated Pruritus: Nikaia-1Journal of the American Academy of Dermatology · 2026
6. Phase II randomised, double-blind, placebo-controlled, dose-ranging study of nemolizumab with an extension period in adult patients with systemic sclerosis: THESSALIA study design and rationaleJournal of Scleroderma and Related Disorders · 2026
7. Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysisDermatology and Therapy · 2026
8. Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisActa Dermato Venereologica · 2026
9. Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User PopulationDermatologic Surgery · 2026
10. A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed StudyDermatology and Therapy · 2026
11. Concomitant Use of Dermo-Cosmetic Skin Care in Aesthetic Procedures: Systematic Review with Expert Panel RecommendationsClinical Cosmetic and Investigational Dermatology · 2026
12. Enhanced Patient Retention With Formal, Structured Facial Assessment and Treatment Planning: A Multi‐Clinic Real‐World AnalysisJournal of Cosmetic Dermatology · 2026
13. Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysisDermatology and Therapy · 2026
14. Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisBritish Journal of Clinical Pharmacology · 2026
15. Physicochemical Properties of Two Poly-L-Lactic Acid Injectable Implants: Potential Impact on Their Biological PropertiesCosmetics · 2026
16. Similar and Limited In Vivo Diffusion for RelaBoNT-A and OnaBoNT-AToxicon · 2026
17. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisJournal of the European Academy of Dermatology and Venereology · 2025
18. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studiesJournal of the European Academy of Dermatology and Venereology · 2025
19. Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview FindingsPatient · 2025
20. Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview FindingsPatient · 2025